Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Leukemia. 2019 Aug 19;34(1):210–223. doi: 10.1038/s41375-019-0540-7

Figure 7. Increased anti-myeloma activities of BCMA-specific memory CTL generated with PLGA/BCMA peptide.

Figure 7.

Figure 7.

Figure 7.

A and B: Increased anti-myeloma activities of BCMA-specific central memory and effector memory CTL generated with PLGA/peptide than free peptide, demonstrated by (A) CD107a degranulation and (B) IFN-γ production, in response to HLA-A2+ myeloma cells (U266). C: Summary of three independent experiments (N=3) showing increased anti-myeloma activities (CD107a degranulation, IFN-γ/IL-2/TNF-α cytokine production) by PLGA/peptide-induced memory CTL (CM > EM) compared to free peptide-induced memory CTL.